You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back



TRELEGY Ellipta once daily is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA.1

Fictional patient, for illustrative purposes only

The Trelegy Ellipta consists of three molecules an ICS, a LAMA and a LABA engineered for an uninterrupted 24-hour effect. These molecules are delivered in the Ellipta device.1,4,5,10-15

Patients with COPD found Ellipta easy to use compared with MDI (92% vs 44%) and Turbohaler (96% vs 55%)7-9

Ellipta device with illustration of the three Trelegy molecules

Who could benefit from TRELEGY Ellipta?


Meet John, he has COPD

He has been prescribed an ICS/LABA regimen as maintenance therapy and is at risk of exacerbation, defined as:

  • A worsening of symptoms, or
  • Has a history of an exacerbation, treated with antibiotics or oral corticosteroids, in the past 12 months

Learn how COPD impacts patients like John

Learn how TRELEGY Ellipta could benefit patients like John

Spotting the Risk: Why Trelegy for COPD patients at risk of exacerbation*?

This video will guide you trough why Trelegy Ellipta is beneficial for COPD patients at risk of exacerbation*

Trelegy prescribing information and adverse event reporting information

POM. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000

*with worsening of symptoms, or a history of an exacerbation, treated with antibiotics or oral corticosteroids, in the past 12 months.

PM-IE-FVU-WCNT-230003 | Date of Preparation: April 2023

TRELEGY Ellipta: Not all COPD treatments are the same

Molecule Design Story

Image of COPD attacking

TRELEGY Ellipta has been intentionally designed to provide your patients with sustained efficacy from today, so they can expect more from tomorrow1-3

Three molecules specifically selected for their long-acting duration of action2-6

All delivered in the easy-to-use Ellipta device7-9

  • TRELEGY Ellipta safety profile

    Common adverse reactions: pneumonia, upper respiratory tract infection, bronchitis, pharyngitis, rhinitis, sinusitis, influenza, nasopharyngitis, candidiasis of mouth and throat, urinary tract infection, headache, cough, oropharyngeal pain, constipation, arthralgia, back pain1

    Pneumonia: in common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with TRELEGY Ellipta, including pneumonia requiring hospitalisation. There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index and severe COPD1

    Cardiovascular: cardiovascular effects, such as cardiac arrhythmias (e.g. atrial fibrillation and tachycardia), may be seen after the administration of muscarinic receptor antagonists and sympathomimetics, including umeclidinium and vilanterol, respectively. Therefore, TRELEGY Ellipta should be used with caution in patients with unstable or life-threatening cardiovascular disease1


ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; QoL, quality of life


  1. TRELEGY Ellipta SmPC, 2022. Available at Accessed January 2023.
  2. Lipson DA et al. Am J Respir Crit Care Med 2017; 196:438–446.
  3. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
  4. Kempsford R et al. Pulm Pharmacol Ther 2013; 26:256–264.
  5. Lainé DI et al. J Med Chem 2009; 52:2493–2505.
  6. Daley-Yates PT. Br J Clin Pharmacol 2015; 80:372–380.
  7. Van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  8. Svedsater H et al. BMC Pulm Med 2013; 13:1–14.
  9. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873–1880.
  10. Daley-Yates PT et al. Br J Clin Pharmacol 2020. doi: 10.1111/bcp.14406.
  11. Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016; 11:719–730.
  12. Laine DI. Exp Rev Clin Pharmacol 2010; 3:43–53.
  13. Slack RJ et al. J Pharmacol Exp Ther 2013; 344:218–230.
  14. Hanania N et al. Chest 2012; 142:119–127.
  15. Biggadike K et al. J Med Chem 2008; 51:3349–3352.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trelegy is a registered trademark of the GlaxoSmithKline group of companies.

TRELEGY Ellipta was developed in collaboration with

Innoviva logo

Last updated: January 2023 PM-IE-FVU-WCNT-220011